Endpoint
Activities of daily living score
The performance of the basic activities of self care, such as dressing, ambulation, or eating.
CAT:outcome/activities-of-daily-living-scorereported in score2 findings from 2 compounds
What moved it
How to read these marks2 findings · 2 compounds · 2 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| Ginkgo biloba | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| melatonin | no effect | 1 | Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence. |
Every finding here is a null result.
Measured, no effect detected
2 findings
Ginkgo biloba — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There were no statistically significant differences in ADL change scores between ginkgo and placebo, with SMD = -0.32 (95% CI -0.66; 0.03, z = 1.77, N = 6, p = 0.08) (Figure.”
Quoted verbatim from Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 120-240 mg daily; where a trial studied several dose levels the higher-dose arm was used
- Population
- Adults with mild to moderate Alzheimer's disease, vascular dementia or mixed dementia, pooled across six randomised trials whose activities-of-daily-living instruments were not harmonised (GERRI, GBS-ADL, ADL-IS, NAA, NAB).
Effect -0.32 standardised mean difference, 95% CI -0.66 to 0.03
Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.2010PMID:20236541Permalink
melatonin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“From two studies, we found no effect of melatonin on cognition or performance of activities of daily living (ADL).”
Quoted verbatim from Pharmacotherapies for sleep disturbances in dementia.. - Study
- meta-analysis
- Population
- patients with moderate-to-severe Alzheimer's disease dementia and an identified sleep disturbance, melatonin doses up to 10 mg; no specific ADL instrument named
Pharmacotherapies for sleep disturbances in dementia.2016PMID:27851868Permalink
How it is measured
Score on a validated basic activities of daily living scale (Barthel Index, Katz ADL, or equivalent) rating independence in self-care tasks such as feeding, transferring, toileting and bathing. Where the review pooled unharmonised instruments the estimate is a standardised mean difference; the instrument, or the fact that none was named, is recorded with each finding. The dementia literature reports this as the ADL change score or ADL change scores.
Measured, not recorded
- Subject
- activities of daily living score
- Measurements
- 1 measurement
- Recorded as a finding
- No
Show what was measured
activities of daily living score
no effect
Not recorded as a finding: bundled with sleep efficiency, circadian markers and depression in one non-specific statement with no per-endpoint estimate
Effects on sleep efficiency, circadian markers, depression and activities of daily living were small and nonsignificant.
PMID:41240058 · one of two readings recorded this
Sources cited
2 papers
- Subject
- activities of daily living score
- Findings
- 2
- Papers
- 2